PETALING JAYA: Supercomnet Technologies Bhd
is anticipated to see improvement in earnings for the financial year 2024 (FY24), driven by its medical segment.
TA Research said it expects the medical segment to continue to grow this year, as the group is pursuing opportunities in expanding sales to existing customers, progressing towards commercial production of new products and shifting to producing whole devices to enhance the group’s margins.
Key customers such as New York-listed Edward Lifesciences Corp (ELC) and Denmark-based Ambu are expected to increase their orders.
...